Great scientific tools aren't built in isolation 👥 For @Jens_Luebeck, Paul Mischel, @VineetBafna3 and the rest of team eDyNAmiC, developing new ways to detect and analyse extrachromosomal DNA (ecDNA) in cancer means bringing together expertise from across disciplines, and key collaborators such as Jill Mesirov. The eDyNAmiC team spans computational scientists, cytogeneticists, clinicians, mathematicians and patient advocates, each bringing a different perspective to the challenge. In our latest challenge update, Jens explains how the team's workflow, AmpliconSuite, is helping researchers identify, classify and study ecDNA at scale, accelerating discovery in one of cancer's most fascinating and complex areas. 👉 Read the full story: bit.ly/4ieqyuJ @UCSDMedSchool, @Stanford

We're looking for international, multidisciplinary teams to tackle two major challenges in cancer research: ▶️ Gastroesophageal transformation into cancer: Understand and reverse early tissue changes leading to gastroesophageal cancers. ▶️ Global variation in gastroesophageal cancer: Determine the biological mechanisms underpinning geographical variations in gastroesophageal cancer incidence. With awards of up to $34m available, now is the time to think big. Find out more and apply: bit.ly/3TzupKA Full application deadline: 24 November. @LoiSher

How do we move the dial towards the prevention of gastroesophageal cancer? In @NatureRevCancer, @CharlesSwanton et al. discuss the two targeted Cancer Grand Challenges designed to address critical unmet needs in gastroesophageal cancer. 🔗bit.ly/4e5n2kT Applications are now open, with up to $34M in funding available for bold, interdisciplinary teams from around the world to take on these challenges. Visit our website for more information. bit.ly/4xfm78b

We’re honoured to be included in the latest @AACR Cancer Progress Report, which highlights the remarkable progress being made in cancer research. From breakthroughs in understanding cancer to new approaches to treatment, research is changing what’s possible.

Last week, we announced two new Cancer Grand Challenges on gastroesophageal cancers. What are we looking for? ➡️ Bold ideas ➡️ International research teams ➡️ Diverse expertise from across and beyond the field With awards of up to $34m available, now is the time to think big. Learn more and apply by 24 November: bit.ly/46DSseg

Ever wondered how Cancer Grand Challenges came to be? This article explores our origins and how we enable international teams to tackle some of the toughest questions in cancer research. Proudly founded by @CR_UK and @theNCI.

One bold idea can change everything. After discovering that some autoantibodies can cause severe COVID-19 disease, Paul Bastard is now leading team ATLAS to explore whether autoantibodies also influence cancer risk. The team's research could transform how we think about cancer prevention, detection and treatment. Read Paul’s full interview at bit.ly/4A4Og4B 📹 Includes footage from @InstitutImagine